Hong Kong Transportation Stock News

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...

With a price-to-earnings (or "P/E") ratio of 17.6x Shangri-La Asia Limited ( HKG:69 ) may be sending bearish signals at...

China Nonferrous Mining Corporation Limited recently reported that rehabilitation of the main and auxiliary shafts at Chambishi Southeast Mine was completed in December 2025, allowing the operation to resume full production on 1 January 2026. Alongside this, the company issued 2026 production guidance outlining approximately 484,000 tonnes of overall copper output and diversified by-products, giving investors clearer visibility into future operating volumes and product mix. We will now...

From what we can see, insiders were net buyers in Jacobio Pharmaceuticals Group Co., Ltd.'s ( HKG:1167 ) during the...

You may think that with a price-to-sales (or "P/S") ratio of 8.4x Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) is...

Tiangong International announced that its subsidiary Jiangsu Tiangong Aihe Technology was approved on 16 January 2026 to join the Institute of Energy, Hefei Comprehensive National Science Center’s joint laboratory for developing fusion-oriented advanced metallic materials, including large-scale powder metallurgy 304B7 high-boron steel and new neutron shield steel. This collaboration gives Tiangong direct involvement in controlled nuclear fusion material research, potentially broadening...

Key Insights Significant insider control over Skyworth Group implies vested interests in company growth The largest...

Key Insights Significant control over VISEN Pharmaceuticals by public companies implies that the general public has...

With its stock down 15% over the past three months, it is easy to disregard TUHU Car (HKG:9690). But if you pay close...

Most readers would already be aware that EPS Creative Health Technology Group's (HKG:3860) stock increased...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Ching Lee Holdings Limited's ( HKG:3728 ) price-to-earnings (or "P/E") ratio of 7.5x might make it look like a buy...

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...

While Huili Resources (Group) Limited ( HKG:1303 ) shareholders are probably generally happy, the stock hasn't had...

Viva Biotech Holdings ( HKG:1873 ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...

JTF International Holdings Limited ( HKG:9689 ) shareholders have had their patience rewarded with a 54% share price...

Despite an already strong run, Sheung Yue Group Holdings Limited ( HKG:1633 ) shares have been powering on, with a gain...

Key Insights The considerable ownership by private companies in China National Building Material indicates that they...

Despite an already strong run, Vision Values Holdings Limited ( HKG:862 ) shares have been powering on, with a gain of...

Key Insights The considerable ownership by individual investors in Shanghai Fudan Microelectronics Group indicates that...

China Unicom (Hong Kong) Limited recently appointed Dong Xin as both Chairman and Chief Executive Officer, effective January 14, 2026, consolidating its top leadership roles under a single executive. By bringing in the existing head of China United Network Communications Group and China United Network Communications Corporation, the company is tightening alignment with its state-owned parent structure, which could influence future corporate priorities and governance. We will now examine...

WuXi Biologics recently announced that its Wuxi Drug Product Facility 5 and Drug Product Packaging Center received UK MHRA GMP certifications for commercial ophthalmic biologic manufacturing, alongside the launch of its PatroLabTM digital twin platform for real-time bioprocess monitoring and control. Together, these developments highlight WuXi Biologics’ growing role as a globally compliant manufacturer that is integrating advanced digital technologies to enhance biologics quality and...

In January 2026, Pop Mart International Group Limited (SEHK:9992) began repurchasing shares under a shareholder-approved mandate allowing the buyback of up to 134,294,315 shares, or 10% of its issued capital, funded from legally available resources under Cayman Islands law. This marks the company’s first significant buyback in nearly two years, signaling management’s confidence and a focus on enhancing net asset value and earnings per share. With this renewed repurchase program underway,...